Meet Our Management Teams

Abrax Japan

A future shaped by our extensive global experience

We have assembled a team of highly skilled professionals in medicine, investment, management, and law from around the world. Leveraging Abrax Japan's unique position as a Japanese firm with its technology originated at an American university, we are managing a global company that transcends national borders

Abrax Japan Management Team Members

Jo NARITA
CEO
Our co-founder obtained a bachelor's degree in Economics from Johns Hopkins University in the United States. Jo had a successful career as a Managing Director at multiple financial institutions such as Goldman Sachs and Citibank. In 2020, he co-founded our company with Taku Kambayashi and assumed the role of CEO.
Noritake MAEDA
Ph.D, Director
Appointed as a Director at Abrax in 2023.  Yoshitake obtained a PhD in Pharmacy from Kyushu University and has been affiliated with research institutions both domestically and internationally. He has also served as a visiting faculty member at Chiba University and Hokkaido University. After joining Axil Capital, a venture capital firm specializing in biotech, in 2023, he concurrently serves as a Director at Abrax.
Masahiro YAGI
Ph.D, Director
Appointed as a Director at Abrax in 2022 Masahiro obtained a PhD in Mechanical Engineering from the University of Wisconsin-Madison in the United States. He gained experience at research institutes of Hitachi and Ricoh, and had a long and successful career at Ricoh UK Products. Currently, while leading IDX Co., Ltd. as the CFO, he also serves as a Director at Abrax.
David CASE, JD
Legal Adviser
Appointed as the General Counsel at Abrax in 2020. David obtained a Juris Doctor degree magna cum laude from Syracuse University College of Law in the United States. After gaining experience as an equity partner at Orrick LLP, David founded Asia Pacific Law and currently serves as a partner at Rimon Law. Specializing in intellectual property and venture capital.

Abrax Japan Science Team Members

Taku KAMBAYASHI, MD, Ph.D
CSA
Dr. Taku Kambayashi is a Professor of Pathology at the University of Pennsylvania, specializing in immunology and transfusion medicine. He leads programs in clinical fellows training and pathology resident training. With multiple awards, including the STAT Summit Breakthrough Science Award, he actively contributes to immunology research, publishing widely and mentoring the next generation of scientists.
Zoltan Arany, MD, PhD
SA
Dr. Zoltan Arany is the Samuel Bellet Professor of Cardiology and directs the Cardiovascular Metabolism Program at UPenn's Perelman School of Medicine. His lab studies metabolic pathophysiology in cardiovascular health, focusing on heart failure, diabetes, and maternal heart disease. With over 200 publications, he is a highly awarded researcher, clinician, and mentor in cardiovascular metabolism.
Brian KIM, MD, MTR
SA
Dr. Brian Kim, Sol and Clara Kest Professor of Dermatology at Icahn School of Medicine at Mount Sinai, leads research on neuroimmune mechanisms in skin diseases. His clinical expertise is in chronic itch, and he has directed pivotal clinical trials, contributing to FDA-approved therapies. With over 80 publications, numerous awards, and NIH grants, Dr. Kim's work advances treatments for atopic dermatitis and other inflammatory skin conditions.
Shinji KAWABATA, MD, Ph.D
SA
Dr. Kawabata, an Associate Professor at Osaka Medical and Pharmaceutical University, is a leading expert in boron neutron capture therapy (BNCT). With extensive experience from Ohio State University, he has pioneered BNCT for aggressive brain tumors, using an accelerator neutron source. His team's groundbreaking clinical results mark a major advancement in cancer treatment.

Abrax Australia Pty. Ltd. Team Members

Thomas BURNS, Ph.D
Director, Public Officer, Abrax Australia Pty. Ltd.
Appointed as a Director at Abrax Australia Pty. Ltd. in 2021. Thomas was affiliated with Dr. Taku Kambayashi's research lab at the University of Pennsylvania. He is responsible for designing and overseeing clinical trials in Australia as a pathway to obtaining FDA approval in the United States.
Jo NARITA
Director, Abrax Australia Pty. Ltd.
Our co-founder obtained a bachelor's degree in Economics from Johns Hopkins University in the United States. Jo had a successful career as a Managing Director at multiple financial institutions such as Goldman Sachs and Citibank. In 2020, he co-founded our company with Taku Kambayashi and assumed the role of CEO.
David CASE, JD
Legal Adviser
Appointed as the General Counsel at Abrax in 2020. David obtained a Juris Doctor degree magna cum laude from Syracuse University College of Law in the United States. After gaining experience as an equity partner at Orrick LLP, David founded Asia Pacific Law and currently serves as a partner at Rimon Law. Specializing in intellectual property and venture capital.